Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.62 |
| ▸ | CDK7 | P50613 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701563 | 0.90 | KDR (0.60) | KDRCHEK1CDK7 | |
| SCHEMBL4301212 | 0.84 | CHEK1 (0.72) | CHEK1CDK7 | |
| SCHEMBL4301105 | 0.83 | CHEK1 (0.76) | KDRCHEK1CDK7 | |
| SCHEMBL4298848 | 0.81 | CHEK1 (0.72) | KDRCHEK1CDK7 | |
| SCHEMBL4296206 | 0.81 | CHEK1 (0.72) | KDRCHEK1CDK7 | |
| SCHEMBL4297145 | 0.81 | CHEK1 (0.71) | KDRCHEK1CDK7 | |
| SCHEMBL6179920 | 0.79 | KDR (1.00) | KDRCDK7 | |
| SCHEMBL13701560 | 0.79 | KDR (0.81) | KDR | |
| SCHEMBL4301208 | 0.78 | CHEK1 (0.83) | CHEK1CDK7 | |
| SCHEMBL4293171 | 0.77 | CHEK1 (0.51) | KDRCHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | KDR 3027/4885CHEK1 1/4885CDK7 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.